Mesa Laboratories MLAB Ratios & Valuation
| TTM Q4 '26 | TTM Q3 '26 | TTM Q2 '26 | TTM Q1 '26 | TTM Q4 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Free cash flow margin | 15.9%+0.6pp | 15.3%+0.1pp | 15.2%+1.3pp | 13.9%-3.8pp | 17.7%-0.4pp | |
| Efficiency | ||||||
| Asset turnover | 0.6×0.0× | 0.6×— | —— | —— | —— | |
| Liquidity | ||||||
| Current ratio | 1.7×-0.2× | 1.9×-0.1× | 2×+1.4× | 0.7×0.0× | 0.6×0.0× | |
| Quick ratio | 1.3×-0.2× | 1.5×0.0× | 1.4×+1.0× | 0.5×0.0× | 0.5×0.0× | |
| Cash ratio | 0.4×-0.1× | 0.5×+0.1× | 0.4×+0.3× | 0.1×0.0× | 0.2×0.0× | |
| Leverage | ||||||
| Debt-to-equity | 0.4×+0.1× | 0.4×0.0× | 0.4×-0.6× | 1×-0.1× | 1×0.0× | |
| Debt-to-assets | 0.2×0.0× | 0.2×0.0× | 0.2×-0.2× | 0.4×0.0× | 0.4×0.0× | |
| Valuation | ||||||
| Market capitalization | $542.27M+3.7% | $433.5M+17.6% | $368.65M-31.5% | $537.85M-16.6% | $644.75M-10.0% | |
| Enterprise value | $594.05M-10.4% | $471.14M+13.2% | $416.21M-39.1% | $683.29M-13.0% | $785.15M-8.3% | |
| Price / sales | 2.2×0.0× | 1.8×+0.2× | 1.5×-0.7× | 2.2×-0.5× | 2.7×-0.3× | |
| Price / book | 2.9×-0.4× | 2.3×+0.3× | 2.1×-1.1× | 3.1×-0.9× | 4×-0.6× | |
| EV / sales | 2.4×-0.4× | 1.9×+0.2× | 1.7×-1.1× | 2.8×-0.4× | 3.3×-0.3× | |
| Free cash flow yield | 7.3%-0.8pp | 8.8%-1.3pp | 10.1%+3.9pp | 6.2%-0.4pp | 6.6%+0.6pp | |
| Dividend yield | 0.6%0.0pp | 0.8%-0.1pp | 0.9%+0.3pp | 0.6%+0.1pp | 0.5%+0.1pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Mesa Laboratories's profit margins?
- Mesa Laboratories (MLAB) runs a 56.8% gross margin and a 2.3% operating margin, with a 1.5% net margin.
- Where do Mesa Laboratories's ratios come from?
- Every ratio is computed from Mesa Laboratories's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
